S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 12.04 CHF -0.5%
Market Cap: 162.7m CHF

Net Margin
Santhera Pharmaceuticals Holding AG

-133.7%
Current
-6 012%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-133.7%
=
Net Income
-65.5m
/
Revenue
49m

Net Margin Across Competitors

No Stocks Found

Santhera Pharmaceuticals Holding AG
Glance View

Market Cap
162.7m CHF
Industry
Biotechnology

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

SANN Intrinsic Value
42.64 CHF
Undervaluation 72%
Intrinsic Value
Price
S
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-133.7%
=
Net Income
-65.5m
/
Revenue
49m
What is the Net Margin of Santhera Pharmaceuticals Holding AG?

Based on Santhera Pharmaceuticals Holding AG's most recent financial statements, the company has Net Margin of -133.7%.

Back to Top